Abstract: A computer-implemented pre-processed time-delay autoencoder based anomaly detection method are provided for detecting anomalous states of machines arranged in a factory automation (FA) system or a manufacturing production line.

Abstract: According to an embodiment of the inventive concept, a method for matching an actual surgical image and a 3D-based virtual surgical simulation environment, which is performed by an apparatus, includes setting POI information during surgery at each of surgery steps in a pre-stored surgical image obtained by performing surgery the same as the actual surgical image, matching the POI information with a virtual pneumoperitoneum model of a patient, which is used for the 3D-based virtual surgical simulation environment, the virtual pneumoperitoneum model being displayed on a UI, recognizing a real-time surgery step of the actual surgical image and determining a location of the POI information for the respective recognized surgery step, and obtaining and displaying image information, which is captured by moving a location of an endoscope inserted into the virtual pneumoperitoneum model to the same location as the determined location of the POI information, through the UI.

Abstract: The present invention relates to methods of overcoming the resistance to an EGFR (Epidermal Growth Factor Receptor)-targeting antibody through a peptide that binds specifically to neuropilin-1 (NRP1). Moreover, the present invention relates to a fusion antibody in which a peptide that binds specifically to NRP1 is fused to an EGFR-targeting antibody, and to a composition of overcoming the resistance to an EGFR-targeting antibody alone by co-administration of the EGFR-targeting antibody and an NRP1-binding peptide-fused Fc. In addition, the fusion antibody according to the present invention, in which the NRP1-specific binding peptide is fused to an EGFR-targeting antibody, overcomes the resistance to the EGFR-targeting antibody alone in pancreatic cancer. Furthermore, the fusion antibody, in which the NRP1-specific binding peptide is fused to the EGFR-targeting antibody, also overcomes resistance to the EGFR-targeting antibody alone even in lung cancer.

Abstract: The inventive concept provides a substrate treating apparatus. The substrate treating apparatus includes a treating container having a treating space; a support unit configured to support and rotate a substrate in the treating space; an exhaust line coupled to the treating container and configured to exhaust an airflow within the treating space; a support frame provided independently of a rotation of the support unit and positioned between the treating container and the support unit; and a guide vane protruding to an outside of the support frame and configured to guide the airflow within the treating space in a downward direction.

Abstract: A dry etching method includes a first step of adsorbing first radicals into a surface of an etching target, wherein the first radicals are contained in first plasma generated from a plasma generator; and a second step of irradiating ion-beams extracted from second plasma generated from the plasma generator onto the surface of the etching target into which the radicals have been adsorbed, thereby desorbing a surface atomic layer of the etching target, wherein the first step is performed such that: a positive potential greater than a potential of the first plasma is applied to one or two selected from first to third grids, while a ground potential is applied to the rest thereof; and a negative potential equal to or lower than a potential of the third grid is applied to a substrate support structure.

Abstract: A storage device including: a bridge board to receive a first command; an authenticator to receive user information; and a memory device to receive the first command from the bridge board, the memory device includes a memory controller which determines a status of the memory device, provides status information including the determined status of the memory device to the bridge board, determines the status of the memory device as an unlocked status or a locked status, the bridge board includes a transceiver which communicates with the host through an interface, a register which stores interface information, and a bridge board controller which generates a first response to the first command in a format corresponding to the interface using the interface information, and provides the first response to a host, the first response includes a status bit which inhibits or allows a write operation with respect to the memory device.

Abstract: Provided is a CNT film coated substrate in which CNT is fixed to a substrate using a click reaction, so that a CNT film is uniformly formed with a high density and adhesive strength between the CNT film and the substrate is excellent to have high stability to water or an organic solvent. In the case of the conventional CNT film which was manufactured by spin coating, most of CNT was peeled off in a washing process, but in the case of the CNT film coated substrate according to the present invention, a high-density uniform CNT film coated substrate may be manufactured even after washing, and reproducibility between substrates may be secured.

Abstract: A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.

Abstract: An anomaly detector for detecting anomaly in input data comprises an auto-encoder trained to encode the input data and decode the encoded input data to reconstruct the input data. Further, the anomaly detector comprises a classifier trained to determine a reconstruction loss indicative of a difference between the accepted input data and the reconstructed input data, where the reconstruction loss includes a weighted combination of a plurality of loss functions evaluating reconstruction losses of a plurality of parts of the reconstructed input data, different types of loss functions, or both. The classifier is further configured to detect an anomaly in the reconstructed input data when the reconstruction loss is above a threshold.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

Abstract: The present disclosure provides a heating, ventilation, and air conditioning (HVAC) system including interconnected artificial neural networks trained for respective subsystems that are required for building temperature control. The HVAC system includes: an air conditioning sensor units installed in or outside a building to detect environmental data; an HVAC device configured to supply thermal energy into an inner space of the building using input power; and a predictive controller configured to generate operational data based on the environmental data and control the HVAC device by adjusting the input power.

Abstract: Disclosed are a speech processing method and a speech processing apparatus in a 5G communication environment through speech processing by executing embedded artificial intelligence (AI) algorithms and/or machine learning algorithms. The speech processing method includes determining a temporary pause of reception of a first spoken utterance, outputting a first spoken response utterance as a result of speech recognition processing of a second spoken utterance received after the temporary pause, determining, as an extension of the first spoken utterance, a third spoken utterance that is received after outputting the first spoken response utterance, deleting, using a deep neural network model, a duplicate utterance part from a fourth spoken utterance that is obtained by combining the first and the third spoken utterance, and outputting a second spoken response utterance as a result of speech recognition processing of the fourth spoken utterance from which the duplicate utterance part has been deleted.

Abstract: Disclosed are a speech processing method and apparatus therefor which execute an installed artificial intelligence algorithm and/or machine learning algorithm to perform speech processing in a 5G communication environment.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

Abstract: Provided is a pharmaceutical composition for preventing or treating inflammatory bowel disease (IBD) comprising a mixed extract of at least two of Aucklandia lappa Decne, Terminalia chebula Retzius, and Zingiber officinale Rosc. as an active ingredient and a method thereof, and more specifically, to a pharmaceutical composition having an inhibitory effect on monocyte adhesion in intestinal epithelial cells, an effect of inhibiting the production of inflammatory cytokines, an effect of ameliorating colitis in an animal model of dextran sodium sulfate (DSS)-induced colitis, and an effect of ameliorating Crohn's disease in an animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease.

Abstract: Provided is a composition for preventing, improving or treating obesity, which includes a Platycodon grandiflorum extract as an active ingredient and a method for preparing the extract with an improved anti-obesity effect. The extract shows an effect of inhibiting increases in body weight and fat mass caused by a high-fat diet for normalization, an increase in fasting blood glucose and a decrease in energy expenditure in a diet-induced obesity mouse model. Further, compared to an extract prepared by a conventional extraction method, the Platycodon grandiflorum extract shows a more excellent effect of inhibiting increases in body weight and fat mass, fasting blood glucose, and blood lipid and adipokine contents in experiments, resulting in an excellent anti-obesity effect. Therefore, the Platycodon grandiflorum extract prepared is expected to be useful for preventing obesity and treating obesity-related complications that can be caused by an increase in fat mass as well as obesity.

Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.

Abstract: A display device according to an embodiment includes a display panel and a protection layer that is disposed on the display panel, wherein the protection layer includes: a first protection layer; a metal layer that overlaps the first protection layer and includes a hole; and an adhesive layer disposed between the first protection layer and the metal layer. The adhesive layer includes a first area disposed between the first protection layer and the metal layer, and a second area and a third area that are disposed in the hole, wherein a peeling strength of the second area and a peeling strength of the third area are different from each other.

Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.

Abstract: Disclosed is an apparatus for collecting a by-product in a semiconductor manufacturing process. An objective of the present invention is to provide an apparatus for collecting a by-product such that exhaust gas having great amount of light gas is coagulated while having sufficient residence time in a long flow path, whereby the exhaust gas is collected as a high-density by-product. For this purpose, the apparatus includes: a housing receiving and discharging introduced exhaust gas and configured with a horizontal vortex plate; an upper plate covering an upper portion of the housing; an internal collecting tower provided with a collecting tower cover and a seed eliminating fin to extend a flow path and residence time of the exhaust gas; a heater having a heat conduction plate; and an extended discharging pipe configured to extend the flow path and residence time of the exhaust gas and discharge the exhaust gas.